close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

78.18 -1.11 (-1.40%)
Streaming Delayed Price Updated: 1:18 PM EDT, Jul 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 629,426
Open 79.13
Bid (Size) 78.15 (500)
Ask (Size) 78.30 (200)
Prev. Close 79.29
Today's Range 77.95 - 79.48
52wk Range 39.37 - 86.74
Shares Outstanding 141,797,854
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
From Ionis Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
-1.9%
-1.9%
1 Month
+3.7%
+3.7%
3 Month
+4.1%
+4.1%
6 Month
-1.0%
-1.0%
1 Year
+97.9%
+97.9%

More News

Read More
News headline image
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now ↗
Via InvestorPlace
Ionis Pharmaceuticals (NASDAQ:IONS) Shares Surge After Crushing Q1 Estimates and Raising Full-Year Guidance ↗
Via Chartmill
News headline image
Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts ↗
Via MarketBeat
News headline image
Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference ↗
Via MarketBeat
News headline image
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis to host 2026 virtual Annual Meeting of Stockholders
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis to present at upcoming investor conferences
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis (IONS) Q1 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Ionis reports first quarter 2026 financial results and highlights progress on key programs
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis (IONS) Q4 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis to hold first quarter 2026 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss
Via MarketMinute
News headline image
When Insider Selling Is a Good Thing: 2 Stocks to Watch ↗
Via MarketBeat
News headline image
Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position ↗
Via The Motley Fool
News headline image
Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy? ↗
Via The Motley Fool

Frequently Asked Questions

Is Ionis Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Ionis Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Ionis Pharmaceuticals, Inc. - Common Stock trade on?
Ionis Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock is IONS on the Nasdaq Stock Market
What is the current price of Ionis Pharmaceuticals, Inc. - Common Stock?
The current price of Ionis Pharmaceuticals, Inc. - Common Stock is 78.18
When was Ionis Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Ionis Pharmaceuticals, Inc. - Common Stock was at 07/01/26 01:18 PM ET
What is the market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock is 11.09B
How many shares of Ionis Pharmaceuticals, Inc. - Common Stock are outstanding?
Ionis Pharmaceuticals, Inc. - Common Stock has 11B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today